**Exhibit      10.8**

**THIS      AMENDED AND RESTATED LICENSE AGREEMENT is**
** **
**made      as of April 3, 2003**

**between:**

| (1) | Elan                Pharmaceuticals, Inc., a Delaware corporation laving a place of business                at 800 Gateway Blvd., San Francisco, California                94080; |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | IE                Oncology Company Limited, an international business company incorporated                under the, laws of Barbados and having its registered office at Bishop's                Court Hill, St. Michael, Barbados;                and |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Inex                Pharmaceuticals Corporation, a company duly amalgamated and validly                existing under the laws of British Columbia and having its principal                place                of business at 100,8900                Glenlyon Parkway, Burnaby, British Columbia,                Canada. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**and      acknowledged and agreed to by:**

| (1) | **Elan                Corporation, plc.,**a                public limited company incorporated** **under                the                laws of* *Ireland,                and having its registered office at Lincoln House, Lincoln Place,                Dublin                2, Ireland; |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | **Elan                Pharma International ltd.**incorporated                under the laws of Ireland, and -having its registered office at WIL                House,                Shannon Business Park, Shannon, County                Clare, Ireland;                and |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | **Inex                International holdings Ltd.,**a                Bermuda exempted limited liability company established under the                laws of                Bermuda with an office at Cedar House, 41 Cedar Avenue, Hamilton,                Bermuda. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**RECITALS:**

| A. | Under                that certain License Agreement dated April 27, 2001, EPIL (as defined                below), .Elan Corp (as defined below) and Elan (as defined below)                licensed                to IE Oncology (as defined below) certain intellectual property owned,                licensed or controlled by EPlf,, Elan Core or Elan (the "original                License"). |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | The                Original License was issued in connection with the formation of IE                Oncology by the Original Parties (as defined below) for the purposes                of                development of certain oncology                products. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C. | On                or about December 28, 2001, Elan acquired TLC (as defined below),                including the intellectual property formerly owned, licensed, or                controlled by TLC and licensed to IE Oncology under the Original                License. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | The                Original Parties have agreed under a Termination Agreement, of even                date                herewith, to terminate their joint venture -relationship                and for                an Affiliate                of Inex (as defined below) to                acquire all shares of IE Oncology held by EIS (as defined below)                and                certain shareholder loans provided by EIS to IE                Oncology. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| E. | As                part of the termination of the joint venture relationship, Elan,                EPIL,                Elan Corp, IE Oncology, Inex and IIH (as defined below) have agreed                to                amend and restate the Original                License. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1 | **DEFINITIONS;                INTERPRETATION** |
|---|------------------------------------------------|

| 1.1 | **Definitions**.                In                this Agreement unless the context otherwise                requires: |
|-----|------------------------------------------------------------------------------------------------------------------------|

**Affiliate**

**Agreement**

**Amended      Effective Date**

**Confidential      Information**

**Original      Effective Date**

**EIS**

**Elan**

**Elan      Corp**

**Elan      Improvements"**

**Elan      Intellectual Property**

**Elan      JV**

**Elan      Know-How**

**Elan      License**

**Elan      Patents" **

**Elan      Third Party Agreements**

----

**EPIL**

**Field**

**FDA**

**Force**
**Majeure**

**"Governmental      Authority" **

**IE      Oncology**

**IIH**

**Inex**

**Infringement      Claim**

**Licensed      Method**

**Liposome      License**

**MHBV**

**NeXstar      Agreement**

**Original      License**

**Original      Parties**

**Party**

**Products**

----

**Regents’      Agreement**

**Regents'        Patent Rights**

|   | (i) | U.S.                    Patent Application serial no. 220,388 entitled "Improved Method                    for                    Loading                    Lipid-Like Vesicles with Drugs or Other Chemicals" tiled July                    12, 1988                    by                    Rolf Mehlhorn and assigned to The Regents of the University of                    California,                    a continuation                    application of U.S. Patent Application serial no. 776,826 filed                    September                    17, 1985, now abandoned; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | U.S.                    Patent Application serial no. 547,382 entitled “Improved Method for                    Loading Lipid-Like Vesicles with Drugs or Other Chemicals” filed July 3,                    1990 by Rolf Mehlhorn and assigned to The Regents of the University                    of                    California, a continuation application of U.S. Patent Application                    serial                    no. 220,388 f led duly 12,                    1988. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Regents'      Sublicense**

**Regulatory      Application**

**Regulatory      Approval**

**Relevant      Event**

**RHA**

**Term**

**Territory**

**TLC**

**UBC      Agreement**

**United      States Dollar**
**Dollar**
**$**
**US$**

----

| 1.2 | **Interpretation.**                In                this Agreement: |
|-----|----------------------------------------------------------------------|

|   | (i) | The                  singular includes the plural and vice versa, and the masculine                  includes                  the feminine and vice versa and the neuter includes *the                  masculine*and                  the feminine. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | Any                  reference to a Clause or Schedule shall, unless otherwise specifically                  provided, he to a Clause or Schedule of this                  Agreement. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | The                  headings of this Agreement are for ease of reference only and shall                  not                  affect its construction or                  interpretation. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3 | This                Agreement is amended and restated as of the Amended Effective Date. |
|-----|-----------------------------------------------------------------------------------------|

| 2 | **LICENSES** |
|---|--------------|

| 2.1 | Elan                hereby grants to IE Oncology for the                Term: |
|-----|-------------------------------------------------------------------------------|

|   | (1) | a                paid up, exclusive license to the Elan Intellectual Property, excluding                the Regents' Patent Rights, to develop, make, have made, import,                use,                offer for sale and sell the Products in the Meld in the Territory,                subject                to any contractual obligations that Elan may have and rights of third                parties as of the Amended Effective Date with respect to the Elan                Third                Party Agreements (the "**Liposome                License**");                and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | subject                to (i) a license granted to TLC in the Regents' Agreement; and (ii)                the                terms, conditions and limitations of the Regents' Agreement, a                non-exclusive sublicense to the Regents' Patent Rights to make, have                made,                use, and sell the Products in the Field in the Territory and a                non-exclusive sublicense to practice the Licensed Method, subject                to                any contractual obligations that Elan may have and rights of third                parties                as of the Amended Effective Date with respect to the Elan Third Party                Agreements ("**Regents'                Sublicense**") |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Elan      License**

| 2.2 | **Sublicensing                by IE Oncology** |
|-----|------------------------------------------------|

|   | (1) | Subject                to the prior written consent of Elan, which shall not be unreasonably                withheld or delayed and any required third party consent under the                Elan                Third Party Agreements, IE Oncology shall be entitled to grant sublicenses                in respect of the Elan License to, as applicable, develop, make or                have                made, import, use, offer for sale and sell the Products in the Field                in                one or more countries of the                Territory. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Any                sublicense granted hereunder shall be pursuant to a written agreement,                which agreement shall be subject to the written approval of Elan,                such                approval not to be unreasonably withheld or delayed, on the same                terms                mutatis mutandis as the tees                of this Agreement insofar as they are applicable (``Sublicense                Agreement"), but excluding the tight to grant a further sublicense.,                other                than 'to Affiliates of a                sublicensee. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (3) | Elan                shall have the right to enforce the tees of any Sublicense Agreement                relating to the intellectual property included in the Elan License                and                shall be named a third party beneficiary thereunder; provided, however                that Elan will not be a party to, any Sublicense                Agreements. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ** **(4) | All                Sublicense Agreements and all rights and licenses granted thereunder                shall                automatically terminate for the country or countries covered by the                sublicense if this Agreement                terminates, howsoever terminated. |
|--------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (5) | IE                Oncology and Inex shall remain jointly and severally liable and                responsible for all acts and omissions of any sublicensee, as if                they were                acts and omissions by IE Oncology and                Inex. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3 | The                Parties intend that the Elan License shall be deemed to be "intellectual                property" as defined in Section 101(56) of the united States Bankruptcy                Code, as amended the "Code"), and that this Agreement shall be governed                by                Section 365(n) of the Code in the event a bankruptcy or similar proceeding                is commenced with respect to .Elan and that IE Oncology may elect                not to                terminate this Agreement in the event Elan or a bankruptcy trustee                rejects                this Agreement. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3 | **INTELLECTUAL                PROPERTY** |
|---|------------------------------------------|

| 3.1 | **Ownership                of Intellectual Property****.** |
|-----|------------------------------------------------------------|

| (1) | Elan                owns and shall remain the owner of the Elan Intellectual Property. |
|-----|----------------------------------------------------------------------------------------|

| 3.2 | **Patent                Prosecution and                Maintenance.** |
|-----|-----------------------------------------------------------------------|

|   | (1) | Elan,                at its sole discretion and expense,                may: |
|--------|-----|------------------------------------------------------------------------------|

|   | (i) | secure                  the grant of any patent applications within the Elan Intellectual                  Property; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------|

|   | (ii) | file                  and prosecute patent applications on patentable inventions and                  discoveries                  relating to the same; |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |   |
|--------|--------|--------|
|   | (iii) | defend                  all such applications against third party oppositions;                  and |
|--------|-------|-----------------------------------------------------------------------------------------------------|

|   |   |   |
|--------|--------|--------|
|   | (iv) | maintain                  in force any issued letters patent relating to the                  same. |
|--------|------|-----------------------------------------------------------------------------------------------------|

|   | (2) | IE                Oncology shall, and shall cause its permitted sublicensces to, promptly                notify Elan of any Elan Improvements. IE Oncology shall, and shall                cause                its permitted sublicensees                to, fully cooperate with Elan, at Elan's expense, in perfecting Elan's                ownership and other proprietary rights in respect of any of the Elan                Improvements and shall execute and deliver to Elan any documents                that Elan                may reasonably require with respect                thereto. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | Elan                will use reasonable efforts to keep IE Oncology informed of the course                of                any decision to abandon a pending or issued claim under the Elan                Patents                its any country or country in the Territory in which such Elan Patents                are                currently maintained. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.3 | Third                Party Agreements. |
|-----|----------------------------------------|

|   | (1) | During                the term of this Agreement Elan may, in its sole discretion, continue                to                maintain or terminate, in whole or in part (including any rights                or                licenses granted to Elan thereunder) the Regents' Agreement. Elan                will                keep IE Oncology informed of any anticipated material change in status                of                the Regents' Agreement: that, to Elan's knowledge, would result in                the                Regents' Agreement or any portion thereof (including any license                granted                to Elan thereunder) being                terminated. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | If                Elan decides, in its sole discretion, that it does not wish to continue                to                maintain the Regents' Agreement (or any portion thereof), then, ninety                (90) days prior to voluntarily surrendering its rights under or                terminating the Regents' Agreement, Elan will advise IE Oncology                in                writing of such decision and, at Elan's option, request that IE                Oncology: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | pursuant                  to a written agreement acceptable to both Elan and IE Oncology,                  undertake                  to perform all of (or the relevant portion of) Man's obligations                  thereunder on behalf of Elan, including payment of all amounts                  due under                  the Regents' Agreement, in which case the Regents' Agreement shall                  continue in                  full force and                  effect; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | pursuant                  to a written agreement acceptable to Elan, IE Oncology and The                  Regents of                  the University of California, take assignment of, or designate                  a nominee                  for the assignment of, the Regents' Agreement, subject to the consent                  of                  IE Oncology, The Regents of the University of California and any                  other                  required consent and upon such terms and conditions as Elan, IE                  Oncology                  (or its nominee) and The Regents of the University of California                  may                  agree; or |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | negotiate                  in good faith with The Regents of the University of California                  to obtain a                  license, at IE Oncology's sole cost and expense, to the Regents'                  Patent                  Rights in the Field and Elan shall reasonably assist and cooperate                  with IE                  Oncology in obtaining such a license from The Regents of the University                  of California. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | IE                Oncology and Inex shall jointly and severally indemnify, defend and                hold                Elan and its Affiliates harmless against any and all actions, claims                and                proceedings (whether successful or otherwise), losses, responsibilities,                damages; liabilities, injuries, costs and expenses, including reasonable                attorneys' fees, arising out of the performance or breach of the                obligations undertaken by IE Oncology pursuant to Clause 3.3(2)(1)                and/or                pursuant to an assignment of the Regents' Agreement to IE Oncology                or its                nominee pursuant to 3.3(2)(ii). |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.4 | **Enforcement,** |
|-----|------------------|

|   | (1) | IE                Oncology shall. promptly notify Elan In                writing                of any actual or alleged unauthorized use of the Elan Intellectual                Property in the Field in the Territory by a third party of which                it                becomes aware and shall provide Elan with any available: evidence                of such                unauthorized use. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Elan                shall have the right in its discretion, but not the obligation, to                enforce                for Elan's own benefit (including by agreement or by litigation)                Elan's                intellectual property rights under the Elan Intellectual Property.                IE                Oncology and Inex shall reasonably cooperate with Elan to enforce                such                rights, provided that IE Oncology and Inex shall be reimbursed for                reasonable out-of-pocket expenses incurred in providing such cooperation.                Elan shall advise IE Oncology and Inex of any such suit or proceedings                that it may commence. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | Should                Elan decide not to enforce its rights under the Elan Intellectual                Property                against such unauthorized use in the Field, within a reasonable period,                but in any event within 20 days after receiving written notice of                such                actual or alleged unauthorized use, IE Oncology may initiate such                proceedings in IE Oncology's name, at IE Oncology's sole cost and                expense                and for IE Oncology's sole benefit. Elan will lend its name to such                action                on IE Oncology's behalf as necessary, unless Elan believes in good                faith                that such an action may be illegal, without merit or harmful to Elan's                business strategy. IE Oncology shall advise Elan of any such suit                or                proceedings commenced by IE                Oncology. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | The                Party bearing the cost of such action or proceeding shall be entitled                to                retain all proceeds of such action or proceeding, after reimbursement                to                the other Parties hereto of any reasonable out-of-pocket expenses                (including reasonable attorneys' fees)                that are incurred as a result of such other Party's participation                in such action or                proceeding. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5 | **Defense.** |
|-----|--------------|

|   | (1) | Each                of IE Oncology and Elan shall promptly notify the other in writing                of any                claim or proceedings made against IE Oncology or Elate, as the case                may                be, alleging infringement or other unauthorized use                of                the proprietary rights of a third party arising from the exploitation                of                the Elan Intellectual Property, including the manufacture, importation,                use, offer for sale, sale or other commercialization of the                Products. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Subject                to Clause 8.6, Elan shall have the right, but not the obligation,                to take                over the conduct and control                of                any Infringement Claim brought against Elan (."Step-In Right"); provided,                however, that IE Oncology's and Inex's respective indemnify obligations                under Clause 8.4 shall continue. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4 | **MANUFACTURING/EXPLOITATION** |
|---|--------------------------------|

| 4.1 | IE                Oncology will be solely responsible for the development, manufacture,                storage, handling, packaging, promotion, distribution., marketing                and sale                of the Products in each country of the Territory and for ensuring                that all                such activities are in strict compliance with all the legal and regulatory                requirements of each country in the Territory (including, for the                avoidance of doubt, all legal and regulatory requirements relating                to                patent marking). |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | All                advertising, promotional materials and marketing and any costs and/or                expenses associated therewith in respect of the Products shall be                the sole                responsibility of IE Oncology. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.3 | IE                Oncology shall research, develop, make, have made, import, export,                use,                offer for sale and sell the Products in accordance with all statutes,                regulations and requirements of the FDA and other RDAs, including                without                limitations, cGMP, cGLP, cGMP                regulations. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4 | For                the avoidance of doubt, Elan shall have no responsibility of any                nature                whatsoever to carry out any work or activity of the kind described                in this                Clause 4 or any other work or activity whatsoever, otherwise than                as                expressly agreed in this Agreement. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5 | **REGULATORY                APPROVALS** |
|---|-----------------------------------------|

| 5.1 | For                the avoidance of doubt, IE Oncology shall have full responsibility                for its                dealings with the FDA and other RHAs relating to the Products and                Elan                shall                have no responsibility                of any nature relating thereto; provided, however, that IE Oncology                shall                promptly advise Elan of any notices or other communications relating                to                the safety of any Products. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2 | Any                and all Regulatory Applications filed by IE Oncology or its permitted                sublicensees for the products shall be the property of IE                Oncology. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6 | **INSURANCE** |
|---|---------------|

** **

| 7 | **FINANCIAL                PROVISIONS** |
|---|-----------------------------------------|

| 7.                  1 | **Original                  License Fee****.**                  Elan confirms that at the Original Effective Date IE Oncology paid,                  in cash, to Elan                  Corp and certain of its Affiliates, a non-refundable license fee                  (the                  "Original License Fee"). The Parties confirm that the Original                  License Fee                  was not, and is not subject to future performance obligations of                  Elan to                  IE Oncology or Inex, and that other than the Original License Fee,                  which                  has been paid, no other fee, royalty or payment is payable by IE                  Oncology                  or any affiliate of IE Oncology to Elan or any Affiliate in respect                  of                  this Agreement. |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2 | **Third                  Party Fees.**                  IE                  Oncology and Inex shall be jointly and severally liable and responsible                  for royalties, milestones, or other payments, if any arising under                  the                  Elan Third Party Agreements from and after the Amended Effective                  Date as a                  result of the grant of rights under the Elan License hereunder                  and/or from                  the exercise of any of the rights granted under the Elan License,                  including without limitation, the process of the commercialization                  or                  other exploitation of Products. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8 | **REPRESENTATIONS                AND WARRANTIES** |
|---|---------------------------------------------------|

| 8.1 | Elan                represents and warrants to IE Oncology and Inex, as of the Amended                Effective Date, as follows: |
|-----|-----------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | with                  respect to the E1an Intellectual Property as it relates to the                  Products: |
|--------|-----|-----------------------------------------------------------------------------------------------------------------|

----

|   | (i) | Elan                  has the right to grant the Liposome                  License; |
|--------|-----|-------------------------------------------------------------------------------------|

|   | (ii) | there                  are no agreements between Elan and any third party that conflict                  with the                  Liposome License; |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | the                  patents and patent applications included in the Elan patents are                  free and                  clear of encumbrances and liens;                  and |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iv) | Elan                  has not received written notice of any third party claims or proceedings                  of infringement of such third party's intellectual property rights                  in                  connection with the Elan Intellectual Property                  in relation to the Field. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | With                  respect to the Regents' Patent Rights as it relates to the                  products: |
|--------|-----|-------------------------------------------------------------------------------------------------------------|

|   | (i) | the                  Regents'                  Agreement is in good standing and in full force and                  effect; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | Elan                  has not granted any sublicenses to any third party under the Regents                  Patent Rights that conflict with the Regents' Sublicense;                  and |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | Elan                  has not received written notice of any third party claims or proceedings                  of infringement                  of                  such third party's intellectual property rights                  in connection                  with the Regents' Agreement in relation to the                  Field. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | IE                Oncology represents and warrants to Elan as of the Amended Effective                Date,                as follows: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | IE                Oncology has the right to enter into this Agreement;                and |
|--------|-----|-------------------------------------------------------------------------------------------|

|   | (2) | there                are no agreements between IE Oncology and any third party that conflict                with this Agreement, |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------|

| 8.3 | Inex                represents and warrants to Elan as of the Amended Effective date,                as                follows: |
|-----|---------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | Inex                has the right to enter into this Agreement;                and |
|--------|-----|------------------------------------------------------------------------------------|

|   | (2) | there                are no agreements between Inex and any third party that conflict                with this                Agreement. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | IE                Oncology and Inex shall jointly                and                severally indemnify, defend and hold Elan and its Affiliates harmless                against any and all actions, claims and proceedings (whether successful                or                otherwise), losses, responsibilities, damages, liabilities, injuries,                costs and expenses, including reasonable attorneys' fees, arising                out                of: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | the                research, testing, manufacture, transport, packaging, storage, handling,                distribution, marketing, advertising, promotion or sale of the products                by                IE Oncology, or any of its Affiliates or sublicensees on behalf of                IE                Oncology; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | any                claims or proceedings made or brought against Elan on behalf of any                persons seeking damages for personal injury (including death) and/or                for                costs of medical treatment, which claims relate in any way to the                Products; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | any                Infringement Claim; |
|--------|-----|----------------------------------------|

|   | (4) | any                Elan                Third Party Agreement in connection with Clause 3.3;                and |
|--------|-----|----------------------------------------------------------------------------------------------------------------|

|   | (5) | any                acts or omissions of any                sublicensees. |
|--------|-----|--------------------------------------------------------------------------|

| 8.5 | In                fulfilling its indemnification obligations hereunder, IE Oncology                and Inex                shall (i) reasonably and regularly consult with Elan in relation                to the                progress and status of any action, claim or proceedings; and (ii)                not make                any statements, enter into any settlement agreement or consent to                any                judgment in respect of any actions, claims and/or proceedings, without                Man's prior written consent, which consent shall not be unreasonably                withheld or delayed. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.6 | In                seeking an indemnity from IE Oncology or :Inex hereunder and/or in                exercising its Step-In Right under Clause 3_S(2), Elan                shall: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | fully                and promptly notify IE Oncology of any claim or proceeding, or threatened                claim or proceeding of which it becomes                aware; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | subject                to Clause 3.4{2}, 3.5(2) and Clause 8.5, permit IE Oncology or Inex                to                control the conduct of such claim or                proceeding; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | reasonably                co-operate in the investigation and defense of such claim or proceeding,                at the reasonable cost and expense of IE Oncology and/or Inex, as                the case                may be; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | not                acknowledge to the third party or to any other person the validity                of any                claims of such third party; and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (5) | not                compromise or otherwise settle any claim or proceeding without the                written                consent of IE Oncology, which consent will not be unreasonably withheld                or                delayed; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.7 | **EXCEPT                AS SET FORTH IN THIS CLAUSE 8, ELAN IS GRANTING THE ELAN LICENSE                HEREUNDER                ON AN "AS IS" BASIS WITHOUT REPRESENTATION OR WARRANTY WHETHER EXPRESS                OR                IMPLIED FROM ELAN OR ANY OF ITS AFFILIATES INCLUDING WARRANTIES OF                MERCHANTABILITY OR FITNESS FOR A PARTICULAR. PURPOSE, OR INFRINGEMENT                OF                THIRD PARTY RIGHTS, AND ALL SUCH WARRANTIES ARE EXPRESSLY                DISCLAIMED.** |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**NOTWITHSTANDING      AGREEMENT, NO PARTY OR ANY OF THEIR RESPECTIVE AFFILIATES SHALL RE LIABLE TO      THE      OTHER PARTIES BY REASON OF ANY REPRESENTATION O WARRANTY, CONDITION Off. OTHER      TERM ANY DUTY OF COMMON LAW, OR UNDER THE EXPRESS TERMS OF THIS AGREEMENT,      FOR      ANY CONSEQUENTIAL, SPECIAL**
**INCIDENTAL      Off. PUNITIVE LOSS OR DAMAGE (WHETHER FOR LOSS OF CURRENT O: FUTURE PROFITS,      LOSS OF ENTERPRISE VALUE OR OTHERWISE) AND WHETHER OCCASIONED BY THE NEGLIGENCE      OF THE RESPECTIVE PARTIES, THEIR EMPLOYEES OR AGENTS OR      OTHERWISE.**

| **9** | **TERM                AND TERMINATION** |
|-------|-----------------------------------------|

| 9.1 | This                Agreement supercedes and replaces the Original License and the terms                hereof are deemed-to have come into force can the Amended Effective                Date                and, subject to the rights of termination outlined in this Clause                9 and                the provisions of applicable laws, will expire on a country-by-country                basis in any country, upon the expiration of the life of the last                to                expire patent included in the Elan License in that country (the                "**Term**"). |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2 | If                either Party commits a Relevant Event (as defined below), the other                Party                shall have, in addition to all other legal and equitable rights and                remedies hereunder, the right to terminate this                Agreement. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.3 | For                the purpose of this Clause 9, a "**Relevant                Event**"                is committed by a Party: |
|-----|--------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | if                such Party commits a material breach of any of the provisions of                this** **Agreement,                and fails to cure the same within 60 days after receipt of a written                notice from the other Party hereto giving full particulars of the                breach                and requiring it to be remedied; provided, that i f the breaching                Party                has proposed a course of action to cure the breach and is acting                in good                faith to cure same but has not cured the breach by the 60th day,                such                period shall be extended by such period as is reasonably necessary                to                permit the breach to be cured, provided that such period shall not                be                extended by more than 90 days, unless otherwise agreed in. writing                by the                Parties; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | upon                ten (10)                days prior written notice, if such Party goes into liquidation under                the                laws of any applicable jurisdiction (except for the purposes of                amalgamation or reconstruction and in such manner that the company                resulting therefrom effectively agrees to be bound by or assume the                obligations imposed on that other Party under this                Agreement); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | upon                ten (10) days written notice, if a receiver, administrator, examiner,                trustee or similar officer is appointed over all or substantially                all of                assets of the other Party under the laws of any applicable jurisdiction;                and/or |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (4) | Upon                ten (10) days written notice, if any proceedings are filed or commenced                by                that                other party under bankruptcy,` insolvency or debtor relief laws or                anything analogous to any of the foregoing under the laws of any                applicable jurisdiction occurs in relation to the other                party, |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | In                addition to rights of termination provided elsewhere in this Agreement,                Elan will be entitled forthwith to terminate this Agreement immediately                upon written notice to IE Oncology if IE Oncology, Inex indirectly,                contests or otherwise disputes the ownership, scope, or validity                of any of                the Elan Intellectual Property, or supports any such attack by a                third                party. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10 | **CONSEQUENCES                OF TERMINATION** |
|----|------------------------------------------------|

| 10.1 | Upon                exercise of those rights of termination specified in Clause 9 or                elsewhere                in this Agreement, this Agreement shall, subject to the provisions                of the                Agreement which survive the termination of the Agreement automatically                terminate forthwith and be of no further legal. force or                effect: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | Consequences                of Expiration or Earlier Termination. |
|------|-------------------------------------------------------------------|

|   | (1) | The                following shall be the consequences of expiration or earlier termination                of this Agreement howsoever                terminated: |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | any                sums that were due from                IE Oncology to* *Elan                howsoever prior to the termination or expiry hereof shall be paid                in full                within 30 days of termination of this                Agreement; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | all                confidentiality provisions set out herein shall remain in full force                and                effect; |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | all                representations, warranties and indemnities shall remain in full                force and                effect; and |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (iv) | subject                  to Clause 10.2(2) and Clause 10.2 (3) below, all rights and licenses                  granted to IE Oncology under this Agreement and/or by IE Oncology                  under                  any and all Sublicense Agreements shall cease for the Territory                  ar for                  such particular country or countries in the Territory, as the case                  may be,                  and neither IE Oncology nor any sublicensee may thereafter use:                  (a) the                  Elan Intellectual Property; and/or (b) the Regents' Patent Rights,                  in any                  country or countries of the                  Territory. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | In                the event this Agreement is terminated by Elan for a default of IE                Oncology and/or Inex (other than a termination by Elan for default                by IE                Oncology and/or Inex under Clauses 9.3(2), 9.3(3) and 9.3(4) above)                hereunder, upon the written request of IE Oncology, Elan will negotiate                with a sublicensee (other than Inex) for the survival of such                sublicensee's rights under the Elan License granted to it by IE Oncology                pursuant to a Sublicense Agreement upon terms and conditions no more                onerous or restrictive than as set forth, at Elan's option, in this                Agreement and/or the relevant Sublicense agreement for such sublicensee                and upon such other terms and conditions as Elan and such sublicensee                may                otherwise agree. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | In                the event this Agreement is terminated by Elan for a default of JE                Oncology and/or Inex under Clauses 9.3(2), 9.3(3) and 9.3(4), upon                the                written request of JE Oncology, Elan will offer to each sublicensee                (other                than Inex) a license to the Elan Intellectual Property and Regents"                Patent                Rights to the extent (i} granted to IE Oncology hereunder; or (ii)                previously granted to such sublicensee under the relevant Sublicense                Agreement, upon terms and conditions no more onerous nor restrictive                than                as set forth, at Elan's option, in this Agreement and/or the relevant                Sublicense Agreement and upon such other terms and conditions as                Elan and                such sublicensee may otherwise                agree. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **11** | **CONFIDENTIAL                INFORMATION** |
|--------|---------------------------------------------|

| 11.1 | **Confidential                Information.** |
|------|----------------------------------------------|

|   | (1) | The                Parties agree that it will be necessary, from time to time, to disclose                to                each other confidential and proprietary information, including without                limitation, inventions, works of authorship, trade secrets,                specifications, designs, data, know how and other proprietary information                relating to the Field, the Products, processes, services and business                of                the disclosing Party. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Confidential      Information**

|   | (2) | Any                Confidential Information disclosed by the disclosing Party shall                be used                by the receiving Party exclusively for the purposes of fulfilling                the                receiving Party's obligations under this Agreement and for no other                purpose. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (3) | Save                as otherwise specifically provided herein, and subject to Clause                11.2 and                Clause 11.3, each forty shall disclose Confidential Information of                the                other Party only to those employees, representatives and agents requiring                knowledge thereof in connection with fulfilling the Party's obligations                under this Agreement. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (4) | Any                breach of this Clause I 1 by any person informed by one of the Parties                is                considered a breach by the Party                itself. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (5) | Confidential                Information shall not to include: |
|--------|-----|---------------------------------------------------------------|

|   | (i) | information                  in the public domain; |
|--------|-----|----------------------------------------------------|

|   | (ii) | information                  made public through no breach of this                  Agreement; |
|--------|------|------------------------------------------------------------------------------------------------|

|   | (iii) | information                  which is independently developed by a Party, as evidenced by such                  Party's                  records, without the use or assistance of the other Party's Confidential                  Information; and |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iv) | information                  that becomes available to a receiving Party on a non- confidential                  basis,                  whether directly or indirectly, from a third party, which third                  party did                  not acquire such information on a confidential basis or otherwise                  from the                  disclosing Party hereto. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (6) | The                provisions relating to confidentiality in this Clause 11 shall remain                in                effect during the term of this ,Agreement, and for a period of 10                years                following the expiration or earlier termination of this                Agreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (7) | The                Parties agree that the obligations of this Clause 1I are necessary                and                reasonable in order to protect the Parties' respective businesses,                and                each Party agrees that monetary damages may be inadequate to compensate                a                Party for any breach by the other Party of its covenants and agreements                set forth herein. The Parties agree that any such violation or threatened                violation may cause reparable injury to a Party and that, in addition                to                any other remedies that may be available, in law and equity or otherwise,                each Party shall be entitled to seek injunctive relief against the                threatened breach of the provisions of this Clause 11, or a continuation                of any such breach by the other Party, specific performance and other                equitable relief to redress such breach together with damages and                reasonable counsel fees and expenses to enforce its rights                hereunder. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2 | **Required                Disclosures** |
|------|-----------------------------------------|

|   | (1) | The                receiving party will be entitled to disclose Confidential Information                which the receiving Party is required to disclose pursuant to  |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | a                  valid order of a court or other governmental body;                  or |
|--------|-----|-------------------------------------------------------------------------------------------|

|   | (ii) | any                  other requirement of law; |
|--------|------|------------------------------------------------|

----

| 11.3 | **Announcements** |
|------|-------------------|

|   | (1) | Subject                to Clause 11.2, no announcement or public statement concerning the                existence, subject matter or any term of this Agreement shall be                made by                or on behalf of a Party hereto without the prior written approval                of the                other Party. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The                terms of any such announcement shall be agreed in good faith by the                Parties. |
|--------|-----|----------------------------------------------------------------------------------------------------------------|

|   | (3) | Each                of the Parties shall be entitled to provide a copy of this Agreement                (and                any subsequent amendments hereto) to a potential third party purchaser,                assignee or licensee in connection with a potential purchase or a                potential assignment or grant of license permitted to be made under                this                Agreement; provided that the relevant purchaser, assignee or licensee                has                entered into a customary confidentiality                agreement. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CUSTOMER      COMPLAINTS AND PRODUCT RECALL**

| 12.1 | IE                Oncology shall establish a procedure for formal adverse event handling                and                reporting. |
|------|---------------------------------------------------------------------------------------------------------------------------------------|

| 12.2 | In                the event of any recall of the Products, as suggested or requested                by any                governmental agency, IE Oncology or Inex shall perform the recall                of the                Products in the Territory and in all events the recall costs shall                be                borne by IE Oncology or Inex, as the case may                be. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13 | **GENERAL                PROVISIONS** |
|----|---------------------------------------|

| 13.1 | **Governing                Law; Jurisdiction**.                This Agreement shall be governed by and construed in accordance with                the                laws of the State of New York without regard to its conflict of laws                principles. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.2 | **Impossibility                of Performance; Force Majeure**.                Neither Party to this Agreement shall be                liable for failure or delay in the                performance of any of its obligations hereunder if such failure or                delay                results from Force Majeure, but any such failure or delay                shall                be remedied by such Party as soon as practicable; provided, however,                that,                no Party shall be excused for a failure or delay in the performance                of any                of its payment obligations hereunder, even if such failure or delay                results from Force Majeure. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.3 | **Assignment****.** This                Agreement may not be assigned by any Party hereto without the prior                written consent of the other Parties hereto, save that a                Party: |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | may                assign this Agreement in whole or in part and delegate its duties                hereunder to its Affiliate or Affiliates without such consent; provided,                however, that the assignor will remain liable and responsible for                and                subject to the terms and conditions of this Agreement;                and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | may                assign its rights and obligations to a successor (whether by merger,                consolidation, reorganization or other similar event) or purchaser                of all                or,                substantially all of its assets relating to such Party's technology                related to this Agreement, provided that such successor or purchaser                has                agreed in writing to assume all of such Party's rights and obligations                hereunder and a copy of such assumption                is provided to the                other Parties. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **13.4** | **Notices***.* |
|----------|----------------|

|   | (1) | Any                notice to be given under this Agreement shall be sent in writing                in                English by registered or recorded delivery post or reputable overnight                courier or telefaxed to the following                addresses: |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (2) | Any                notice sent by mail shall be deemed to have been delivered within                7                working days after dispatch or delivery to the relevant courier and                any                notice sent by telefax shall be deemed to have been delivered upon                confirmation of receipt. Notice of change of address shall be effective                upon receipt. Notices by telefax shall also be seat by another method                permitted hereunder. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.5 | **Waiver****.**No                waiver of any right under this Agreement shall be deemed effective                unless                contained                in                a written document signed by the Party charged with such waiver,                and no                waiver of any breach or failure to perform shall be deemed to be                a waiver                of any other breach or failure to perform or of any other right arising                under this Agreement. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.6 | **Severability**.                If any provision in this Agreement is deemed to be invalid, illegal,                void                or unenforceable under any law that is applicable                hereto: |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (1) | such                provision will be deemed amended to conform to applicable laws so                as to be                valid and enforceable; or |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | if                it cannot be so amended without materially altering the intention                of the                Parties, it will be deleted and the validity, legality and enforceability                of the remaining provisions of this Agreement shall not be impaired                or                affected in any way. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.7 | **Further                Assurances**.                At the request of any of the Parties, the other Party or Parties                shall                (and shall use reasonable efforts to procure that any other necessary                parties shall) execute and perform all such documents, acts and things                as                may reasonably be required subsequent                to the signing of this Agreement for assuring to or vesting in the                requesting Party the frill benefit of the terms                hereof. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.8 | **Successors**.                This Agreement                shall he binding upon and enure to the benefit of the Parties hereto,                their successors and permitted                assigns. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| l3.9 | **No                Effect on Other Agreements/Conflict**.                No provision of this Agreement shall be construed so as to negate,                modify or affect in any way the provisions of any other i agreement                between the Parties unless specifically referred to, and solely to                the                extent provided herein. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.10 | **Amendments**.                No amendment,                modification or addition hereto shall be effective or binding on                any Party                unless set forth in writing and executed by a duly authorized                representative of each Party. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.11 | **Counterparts**.                This Agreement                may be executed in any number of counterparts, each of which when                so                executed shall be deemed to be                an original and                all of which when taken together shall constitute this                Agreement. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.12 | **Good                Faith**.                 Each                Party undertakes to act reasonably in giving effect to the provisions                of                this Agreement. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.13 | **No                Reliance**.                Each Party hereby acknowledges that in entering into this Agreement                it has                not relied on any representation or warranty save as expressly set                out                herein or in any document referred to                herein. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.14 | **Relationship                of the Parties**. |
|-------|-------------------------------------------------|

|   | (1) | Nothing                contained in this Agreement is intended or is to be construed to                constitute Elan and IE Oncology as partners or joint venturers or                Elan as                an employee of IE Oncology,                or IE Oncology                as an employee of Elan. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | Neither                Party hereto shall have any express or implied right or authority                to                assume or create any obligations                on                behalf of or in the name of the other Party or to bind the other                Party to                any contract, agreement or undertaking with any                third |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.15 | Whole                Agreement. This                Agreement (including the Schedules attached hereto) sets forth all                of the                agreements and understandings between the Parties with respect to                the                subject matter hereof, and supersedes and terminates all prior agreements                and understandings between the Parties with respect to the Products                in the                Field. There are no agreements or understandings with respect to                the                subject matter hereof, either oral or written, between the Parties                other                than as set forth in this Agreement; provided, however, that nothing                contained in this Agreement shall supercede, terminate or negate                any                provision of the Termination Agreement among the Original Parties                of even                date hereof. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*The      Remainder of This Page is Intentionally Left Blank*

*Signature      Page to Follow*

----

**SIGNED**

**Elan      Pharmaceuticals, Inc.**

**The      Liposome Company, Inc.**

**SIGNED**

**IE      Oncology Company Limited**

**SIGNED**

**Inex      Pharmaceuticals Corporation**

**ACKNOWLEDGED      AND AGREED TO BY:**

**Elan      Pharma International Limited**

**Elan      Corporation, plc**

**Inex      International Holdings, Ltd.**

----